Base de dados : MEDLINE
Pesquisa : E02.931.500 [Categoria DeCS]
Referências encontradas : 394 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 40 ir para página                         

  1 / 394 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384960
[Au] Autor:Martín Algarra S; Soriano V; Fernández-Morales L; Berciano-Guerrero MÁ; Mujika K; Manzano JL; Puértolas Hernández T; Soria A; Rodríguez-Abreu D; Espinosa Arranz E; Medina Martínez J; Márquez-Rodas I; Rubió-Casadevall J; Ortega ME; Jurado García JM; Lecumberri Biurrun MJ; Palacio I; Rodríguez de la Borbolla Artacho M; Altozano JP; Castellón Rubio VE; García A; Luna P; Ballesteros A; Fernández O; López Martín JA; Berrocal A; Arance A
[Ad] Endereço:Medical Oncology, Clínica Universidad de Navarra, Pamplona.
[Ti] Título:Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.
[So] Source:Medicine (Baltimore);96(52):e9523, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The main objective of the study was to evaluate the efficacy and safety of dabrafenib alone or combined with trametinib for compassionate use in patients with metastatic melanoma.This retrospective, observational study involved 135 patients with unresectable stage IIIC or stage IV melanoma from an expanded-access program at 30 Spanish centers.Forty-eight patients received dabrafenib monotherapy and 87 received combination dabrafenib and trametinib; 4.4% and 95.6% of the patients had stage IIIC and IV melanoma, respectively. All patients showed BRAF mutations in their primary or metastatic lesions; 3 were positive for V600K while the remainder had V600E or V600+. A positive response to treatment was reported in 89.3% of the patients. Overall survival rates at 12 and 24 months were 59.6% (95% confidence interval [CI], 52.5-68.9%) and 36.4% (95% CI, 27.8-45%), respectively. Progression-free survival rates at 12 and 24 months were 39.3% (95% CI, 31.1-47.5%) and 21.6% (95% CI, 14.5-28.7%), respectively. Fifty-seven patients (42.2%) reported cutaneous toxicity of any type, mainly hyperkeratosis (14.8%) and rash (11.9%). The most frequent adverse events were pyrexia (27.4%), asthenia (19.3%), arthralgia (16.9%), and diarrhoea (13.2%).Our results suggest that both dabrafenib alone or in combination with trametinib are effective for compassionate use in terms of response and/or survival rates. However, differences in patients' prognostic features ought to be considered. No new findings were revealed regarding the safety profiles of either regimen. This is the first study to evaluate the efficacy of these 2 selective BRAF and mitogen-activated extracellular signal-regulated kinase inhibitors in a real-world setting in Spain.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Imidazóis/uso terapêutico
Melanoma/tratamento farmacológico
Melanoma/patologia
Oximas/uso terapêutico
Piridonas/uso terapêutico
Pirimidinonas/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Ensaios de Uso Compassivo
Feminino
Seres Humanos
Imidazóis/administração & dosagem
Imidazóis/efeitos adversos
Masculino
Meia-Idade
Metástase Neoplásica
Oximas/administração & dosagem
Oximas/efeitos adversos
Piridonas/administração & dosagem
Piridonas/efeitos adversos
Pirimidinonas/administração & dosagem
Pirimidinonas/efeitos adversos
Estudos Retrospectivos
Espanha
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Imidazoles); 0 (Oximes); 0 (Pyridones); 0 (Pyrimidinones); 33E86K87QN (trametinib); QGP4HA4G1B (dabrafenib)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009523


  2 / 394 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29360304
[Au] Autor:Seiler LW; Thomson Reuters Accelus.
[Ti] Título:Long-Term Care: End-of-Life Issues.
[So] Source:Issue Brief Health Policy Track Serv;2017:1-96, 2017 Dec 26.
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Assistência de Longa Duração/organização & administração
Assistência Terminal/organização & administração
[Mh] Termos MeSH secundário: Diretivas Antecipadas
Afroamericanos
Moradias Assistidas
Canadá
Capitação
Ensaios de Uso Compassivo
Comportamento do Consumidor
Aconselhamento
Demência/terapia
Depressão
Europa (Continente)
Grupo com Ancestrais do Continente Europeu
Custos de Cuidados de Saúde
Hispano-Americanos
Cuidados Paliativos na Terminalidade da Vida
Seres Humanos
Reembolso de Seguro de Saúde
Maconha Medicinal
Medicare/economia
Musicoterapia
Enfermagem/recursos humanos
Casas de Saúde
Cuidados Paliativos
Planejamento de Assistência ao Paciente
Direitos do Paciente
Prisioneiros
Qualidade da Assistência à Saúde
Ordens quanto à Conduta (Ética Médica)
Cônjuges
Governo Estadual
Suicídio Assistido
Telemedicina
Doente Terminal
Obtenção de Tecidos e Órgãos
Estados Unidos
Veteranos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Medical Marijuana)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE


  3 / 394 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28831600
[Au] Autor:Candelaria M; Burgos S; Ponce M; Espinoza R; Dueñas-Gonzalez A
[Ad] Endereço:Division de Investigación Clínica, Instituto Nacional de Cancerología, Av. San Fernando 22, Tlalpan, 14080, México, D.F., Mexico. candelariahmgloria@gmail.com.
[Ti] Título:Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
[So] Source:Ann Hematol;96(11):1825-1832, 2017 Nov.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The hypomethylating agents azacytidine and decitabine are unaffordable for many patients with MDS. The combination of the DNA methyltransferase inhibitor hydralazine and the histone deacetylase inhibitor valproate has shown preliminary efficacy in MDS. The aim of this study is to evaluate the clinical efficacy and safety of hydralazine/valproate in a case series of MDS patients treated in a compassionate manner. Hydralazine was dosed according to the acetylation genotype of patients (slow acetylators 83 mg daily; fast acetylators 182 mg daily), and valproate was dosed at 30 mg/kg/day. Both drugs were given daily until disease progression. Response and toxicity were evaluated with the International Working Group criteria and CTCAE, version 4, respectively. Survival parameters were estimated with the Kaplan-Meier method. From 2009 to 2012, 14 patients were treated. The median age ± SD was 55.2 ± 19.52 (range 23-87) years. According to the IPSS, cases were graded as intermediate-1 (n = 8/14; 57.2%) or intermediate-2 (n = 6/14; 42.8%). Responses were as follows: five (35.7%) complete response, one (7.1%) partial response, and two (14.28%) became transfusion independent. The mean duration of response ± SD was 60 ± 35.28 months (range 5-94). Three patients progressed to AML. At a median follow-up of 57 months (range 1-106), the median OS was 27 months. At that point, five patients remained on the treatment, one with partial response and four with complete response. The median OS was not reached in the eight patients who saw a clinical benefit from the treatment, in comparison to an OS of 7 months in the six patients who had no treatment. The combination of hydralazine and valproate is safe and effective in MDS, and its further testing is highly desirable.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Ensaios de Uso Compassivo/métodos
Epigênese Genética/efeitos dos fármacos
Hidralazina/administração & dosagem
Síndromes Mielodisplásicas/tratamento farmacológico
Ácido Valproico/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Ensaios de Uso Compassivo/mortalidade
Epigênese Genética/fisiologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Síndromes Mielodisplásicas/diagnóstico
Síndromes Mielodisplásicas/mortalidade
Estudos Retrospectivos
Taxa de Sobrevida/tendências
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
26NAK24LS8 (Hydralazine); 614OI1Z5WI (Valproic Acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3103-x


  4 / 394 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28767588
[Au] Autor:Gugliandolo A; Caio C; Mezzatesta ML; Rifici C; Bramanti P; Stefani S; Mazzon E
[Ad] Endereço:aIRCCS Centro Neurolesi "Bonino-Pulejo", Via Provinciale Palermo, Messina bSection of Microbiology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
[Ti] Título:Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury: A case report.
[So] Source:Medicine (Baltimore);96(31):e7664, 2017 Aug.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Carbapenem-resistant Enterobacteriaceae infections are a serious health care problem, because of the high mortality. Carbapenem resistance is mainly caused by carbapenemases production, including Klebsiella pneumoniae carbapenemase (KPC). Ceftazidime-avibactam is a new cephalosporin/ß-lactamase inhibitor combination for the treatment of complicated urinary, intra-abdominal infections, and nosocomial pneumonia caused by gram negative, or other serious gram-negative infections. PATIENT CONCERNS: We showed the case of a 27-year-old patient, hospitalized for traumatic brain injury and chest trauma, with KPC-producing Klebsiella pneumoniae infection. DIAGNOSES: Blood and bronchial aspirate culture analysis detected an infection caused by MDR Klebsiella pneumoniae, resistant to meropenem, ertapenem, piperacillin/tazobactam, amoxicillin/clavulanic acid, aztreonam, ceftazidime, cefotaxime, cefepime, amikacin, ciprofloxacin, trimethoprim/sulfamethoxazole, colistin while it showed an intermediate sensitivity to gentamicin and was sensitive to ceftazidime-avibactam. Molecular analyses revealed that the isolate belonged to the epidemic clone sequence type 258 (ST258) carrying blaKPC-3, blaTEM-1, and blaSHV-11genes. INTERVENTIONS: After various combined antibiotic therapies without improvements, he was treated with ceftazidime-avibactam, on a compassionate-use basis. OUTCOMES: With ceftazidime-avibactam monotherapy clinical and microbiological clearance was obtained. A week after the end of the therapy microbiological analysis was repeated and a positive rectal swab for KPC-Klebsiella pneumoniae was found, becoming negative after 1 month. Moreover, the patient did not show any relapses for up to 18 weeks. LESSONS: This case indicates that ceftazidime-avibactam monotherapy could be efficacious against KPC positive Klebsiella pneumoniae infections.
[Mh] Termos MeSH primário: Compostos Azabicíclicos/uso terapêutico
Lesões Encefálicas Traumáticas/complicações
Ceftazidima/uso terapêutico
Infecções por Klebsiella/tratamento farmacológico
Klebsiella pneumoniae
Inibidores de beta-Lactamases/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Lesões Encefálicas Traumáticas/microbiologia
Ensaios de Uso Compassivo
Estado Terminal
Farmacorresistência Bacteriana Múltipla
Seres Humanos
Infecções por Klebsiella/complicações
Klebsiella pneumoniae/efeitos dos fármacos
Klebsiella pneumoniae/genética
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Azabicyclo Compounds); 0 (avibactam, ceftazidime drug combination); 0 (beta-Lactamase Inhibitors); 9M416Z9QNR (Ceftazidime)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170803
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007664


  5 / 394 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28657861
[Au] Autor:Kurolap A; Eshach-Adiv O; Hershkovitz T; Paperna T; Mory A; Oz-Levi D; Zohar Y; Mandel H; Chezar J; Azoulay D; Peleg S; Half EE; Yahalom V; Finkel L; Weissbrod O; Geiger D; Tabib A; Shaoul R; Magen D; Bonstein L; Mevorach D; Baris HN
[Ad] Endereço:Technion-Israel Institute of Technology, Haifa, Israel.
[Ti] Título:Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy.
[So] Source:N Engl J Med;377(1):87-89, 2017 07 06.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Antígenos CD55/genética
Mutação da Fase de Leitura
Enteropatias Perdedoras de Proteínas/tratamento farmacológico
Enteropatias Perdedoras de Proteínas/genética
[Mh] Termos MeSH secundário: Criança
Pré-Escolar
Ensaios de Uso Compassivo
Ativação do Complemento
Complexo de Ataque à Membrana do Sistema Complemento/metabolismo
Diarreia/etiologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Linhagem
Análise de Sequência de DNA
Albumina Sérica/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:LETTER; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (CD55 Antigens); 0 (Complement Membrane Attack Complex); 0 (Serum Albumin); A3ULP0F556 (eculizumab)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1707173


  6 / 394 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28262583
[Au] Autor:Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
[Ad] Endereço:Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany. Electronic address: Stefanie.Zschaebitz@med.uni-heidelberg.de.
[Ti] Título:Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
[So] Source:Eur J Cancer;76:1-7, 2017 May.
[Is] ISSN:1879-0852
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Treatment options for patients with platinum refractory metastatic germ cell tumours (GCT) relapsing after high-dose chemotherapy and autologous stem cell transplantation are limited and survival is poor. Antibodies directed against programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) are currently assessed within clinical trials. We present updated data on our experience with checkpoint inhibitors as a compassionate use off-label treatment attempt for highly-pretreated patients with GCT and provide an overview of the current literature on PD-L1 expression in this rare tumour entity. PATIENTS AND METHODS: We analysed all patients with platinum refractory GCT treated with checkpoint inhibitors at our institutions between 2015 and 2017. Data were retrieved retrospectively from the patient charts. RESULTS: Seven patients were treated with nivolumab or pembrolizumab. Four patients received single-dose treatment and died shortly afterwards due to tumour progression; the remaining three patients received treatment for at least 6 months. No significant treatment toxicity was observed. Long-term tumour response was achieved in two of the three patients, both of them highly positive for PD-L1 staining. INTERPRETATION: We consider checkpoint inhibition to be efficient in carefully selected patients with platinum refractory GCT. However, predictive markers associated with tumour response are not yet known and larger prospective clinical trials are warranted.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Anticorpos Monoclonais/uso terapêutico
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias do Mediastino/tratamento farmacológico
Recidiva Local de Neoplasia/tratamento farmacológico
Neoplasias Embrionárias de Células Germinativas/tratamento farmacológico
Neoplasias Testiculares/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Coriocarcinoma não Gestacional/diagnóstico por imagem
Coriocarcinoma não Gestacional/tratamento farmacológico
Coriocarcinoma não Gestacional/metabolismo
Coriocarcinoma não Gestacional/secundário
Cisplatino/uso terapêutico
Ensaios de Uso Compassivo
Tumor do Seio Endodérmico/diagnóstico por imagem
Tumor do Seio Endodérmico/tratamento farmacológico
Tumor do Seio Endodérmico/metabolismo
Tumor do Seio Endodérmico/secundário
Etoposídeo/uso terapêutico
Seres Humanos
Ifosfamida/uso terapêutico
Neoplasias Pulmonares/diagnóstico por imagem
Neoplasias Pulmonares/secundário
Masculino
Neoplasias do Mediastino/metabolismo
Neoplasias do Mediastino/patologia
Meia-Idade
Neoplasias Embrionárias de Células Germinativas/diagnóstico por imagem
Neoplasias Embrionárias de Células Germinativas/metabolismo
Neoplasias Embrionárias de Células Germinativas/secundário
Compostos de Platina/administração & dosagem
Receptor de Morte Celular Programada 1/metabolismo
Estudos Retrospectivos
Seminoma/diagnóstico por imagem
Seminoma/tratamento farmacológico
Seminoma/metabolismo
Seminoma/secundário
Transplante de Células-Tronco
Teratoma
Neoplasias Testiculares/metabolismo
Neoplasias Testiculares/patologia
Tomografia Computadorizada por Raios X
Transplante Autólogo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0 (PDCD1 protein, human); 0 (Platinum Compounds); 0 (Programmed Cell Death 1 Receptor); 31YO63LBSN (nivolumab); 6PLQ3CP4P3 (Etoposide); DPT0O3T46P (pembrolizumab); Q20Q21Q62J (Cisplatin); UM20QQM95Y (Ifosfamide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170307
[St] Status:MEDLINE


  7 / 394 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28098509
[Au] Autor:Roberts DS; Slattery WH; Chen BS; Otto SR; Schwartz MS; Lekovic GP
[Ad] Endereço:a House Clinic and House Ear Institute , 2100 West 3rd Street, Los Angeles , CA 90057 , USA.
[Ti] Título:'Compassionate use' protocol for auditory brainstem implantation in neurofibromatosis type 2: Early House Ear Institute experience.
[So] Source:Cochlear Implants Int;18(1):57-62, 2017 Jan.
[Is] ISSN:1754-7628
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To report the preliminary outcomes of auditory brainstem implantation (ABI) under a compassionate use protocol for two ABI devices that are not approved by the US Food and Drug Administration. METHODS: A retrospective review was performed of neurofibromatosis type 2 (NF2) patients who underwent microsurgery for vestibular schwannoma (VS) and placement of either the Cochlear ABI541 or Med-El Synchrony ABIs. Peri-operative and device- related complications were reviewed. Audiometric performance was also evaluated. RESULTS: Seven patients received either the Cochlear ABI541 (6) or the Med-El Synchrony ABI (1) after the resection of VS. No device or patient-related complications occurred to date. Surgical times and early audiological performance are similar to our previous experience with the Cochlear ABI24 device. CONCLUSIONS: Early experience with the Cochlear ABI541 and Med-El Synchrony ABI devices under a compassionate use protocol suggest that both devices are safe with comparable utility to the Cochlear ABI24 device.
[Mh] Termos MeSH primário: Implante Auditivo de Tronco Encefálico/instrumentação
Implantes Cocleares
Ensaios de Uso Compassivo
Neurofibromatose 2/cirurgia
Neuroma Acústico/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Audiometria
Implante Auditivo de Tronco Encefálico/métodos
Percepção Auditiva
Cóclea/cirurgia
Aprovação de Equipamentos
Feminino
Seres Humanos
Masculino
Meia-Idade
Neurofibromatose 2/complicações
Neurofibromatose 2/psicologia
Neuroma Acústico/etiologia
Neuroma Acústico/psicologia
Período Pós-Operatório
Estudos Retrospectivos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170119
[St] Status:MEDLINE
[do] DOI:10.1080/14670100.2016.1258203


  8 / 394 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28072813
[Au] Autor:Kreuzer PM; Vielsmeier V; Poeppl TB; Langguth B
[Ad] Endereço:Department of Psychiatry and Psychotherapy, University of Regensburg, Germany; Interdisciplinary Tinnitus Center of the University of Regensburg, Regensburg, Germany.
[Ti] Título:A Case Report on Red Ear Syndrome with Tinnitus Successfully Treated with Transcranial Random Noise Stimulation.
[So] Source:Pain Physician;20(1):E199-E205, 2017 Jan-Feb.
[Is] ISSN:2150-1149
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The red ear syndrome represents a rare symptom complex consisting of auricular erythema associated with painful and burning sensations. It has been described in combination with tinnitus rarely. It has been hypothesized to be etiologically related to altered trigeminal afferent input, temporomandibular disorders, and thalamic dysfunction. OBJECTIVES: The initial objective of applying transcranial random noise stimulation (tRNS) in a case of red ear syndrome in combination with tinnitus was the alleviation of the phantom sounds. STUDY DESIGN: This is a case report on the successful treatment of red ear syndrome with tinnitus by means of transcranial random noise stimulation (tRNS) and a short review on the published cases of this condition. SETTING: We present the case of a 50-year-old woman reporting a simultaneous onset of constant left-sided tinnitus and feelings of warmth accompanied by an intermittent stabbing and/or oppressive pain stretching from the ipsilateral ear to the head/neck/shoulder region, occasionally accompanied by nausea/vomiting and dizziness. After failure of pharmacological treatment attempts, either because of lacking clinical effects (gabapentin, zolmitriptan, and indomethacin) or because of adverse reactions (pregabaline), the patient was offered an experimental neuromodulatory treatment with bitemporal tRNS primarily targeting the tinnitus complaints of the patient. METHODS: tRNS was conducted in 2 - 3 day sessions (stimulation site: bilateral temporal cortex/2.0 mA/10 s on-and-off-ramp/offset 0 mA/20 min/random frequencies 101 - 640 Hz / NeuroConn Eldith DC-Stimulator plus). RESULTS: In 3 consecutive pain attacks repeated sessions of tRNS resulted in substantial alleviation of pain intensity and a prolongation of the interval between attacks. This was an expected finding as the proposed tRNS treatment was initially offered to the patient aiming at an alleviation of the tinnitus complaints (which remained unaffected by tRNS). LIMITATIONS: The reported data derive from compassionate use treatment in one single patient. Application of a sham condition would have been desirable, but is not possible in the context of compassionate use treatment. Nevertheless, we would consider it rather unlikely that the reported effects are purely unspecific as the patient did exclusively report symptom alleviation of pain-related parameters without affecting the tinnitus. CONCLUSIONS: This case report demonstrates the feasibility and therapeutic potential of applying neuromodulatory treatment approaches in red ear syndrome, a rare form of trigemino-autonomal headache. Therefore, it deserves detailed observation in clinical routine applications as well as controlled trials further investigating its neurobiological effects. Key words: Red ear syndrome, pain, trigemino-autonomal headache, chronic tinnitus, transcranial electrical stimulation, random noise stimulation.
[Mh] Termos MeSH primário: Zumbido/terapia
Estimulação Transcraniana por Corrente Contínua
[Mh] Termos MeSH secundário: Ensaios de Uso Compassivo
Feminino
Seres Humanos
Meia-Idade
Dor
Síndrome
Estimulação Magnética Transcraniana
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170721
[Lr] Data última revisão:
170721
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170111
[St] Status:MEDLINE


  9 / 394 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28054734
[Au] Autor:Falsey AR; Koval C; DeVincenzo JP; Walsh EE
[Ad] Endereço:University of Rochester School of Medicine and Rochester General Hospital, Rochester, NY, USA.
[Ti] Título:Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons.
[So] Source:Transpl Infect Dis;19(2), 2017 Apr.
[Is] ISSN:1399-3062
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Respiratory syncytial virus (RSV) may cause fatal lower respiratory tract infection (LRTI) in immunocompromised patients. Ribavirin with or without standard intravenous immunoglobulin (IVIG) is frequently given although efficacy is debated. Infusion of IVIG with high levels of neutralizing antibody against RSV may offer benefit in these patients. METHODS: RI-001 contains standardized levels of high-titer anti-RSV neutralizing antibody and was provided for compassionate use to 15 patients with RSV LRTI who either failed conventional therapy or had significant risk of progression. Patients were treated on day 1 with RI-001 1500 mg/kg, followed 2 days later with 750 mg/kg. Pre- and post-infusion sera were measured for RSV neutralizing antibody. Patient data were analyzed for safety related to infusion of RI-001, and clinical outcomes. RESULTS: Patients ranged in age from 2 months to 71 years and 80% had hematologic malignancy or were bone marrow or hematopoietic stem cell transplant recipients. Administration was well tolerated. Pre-infusion neutralizing titers ranged from 51 to 1765 geometric mean titer (mean 646±519) and all patients demonstrated at least a 4-fold rise (mean 6410±4470) 5-10 days post infusion. Eleven of 15 improved and were discharged from the hospital. Days from positive RSV test to RI-001 treatment was shorter in survivors compared to non-survivors (4.4±2.8 vs. 20.3±21.0 days, P=.02). CONCLUSION: Administration of RI-001 was well tolerated and resulted in significant increases in serum neutralizing antibody titers to RSV. Our data suggest that early identification of RSV and treatment with RI-001 may offer benefit.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/uso terapêutico
Anticorpos Antivirais/uso terapêutico
Antivirais/uso terapêutico
Drogas em Investigação/uso terapêutico
Imunoglobulinas Intravenosas/uso terapêutico
Infecções por Vírus Respiratório Sincicial/tratamento farmacológico
Vírus Sincicial Respiratório Humano/imunologia
Infecções Respiratórias/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Anticorpos Neutralizantes/administração & dosagem
Anticorpos Neutralizantes/efeitos adversos
Anticorpos Antivirais/administração & dosagem
Anticorpos Antivirais/efeitos adversos
Antivirais/administração & dosagem
Antivirais/efeitos adversos
Criança
Pré-Escolar
Ensaios de Uso Compassivo
Drogas em Investigação/administração & dosagem
Drogas em Investigação/efeitos adversos
Feminino
Seres Humanos
Hospedeiro Imunocomprometido
Imunoglobulinas Intravenosas/administração & dosagem
Imunoglobulinas Intravenosas/efeitos adversos
Lactente
Infusões Intravenosas
Aplicação de Novas Drogas em Teste
Masculino
Meia-Idade
Infecções por Vírus Respiratório Sincicial/virologia
Infecções Respiratórias/virologia
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Antiviral Agents); 0 (Drugs, Investigational); 0 (Immunoglobulins, Intravenous)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170106
[St] Status:MEDLINE
[do] DOI:10.1111/tid.12657


  10 / 394 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28051797
[Au] Autor:Castells L; Llaneras J; Campos-Varela I; Bilbao I; Crespo M; Len O; Rodríguez-Frías F; Charco R; Salcedo T; Esteban JI; Esteban-Mur R
[Ad] Endereço:LIver Unit. Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona. Spain.
[Ti] Título: Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.
[So] Source:Ann Hepatol;16(1):86-93, 2017 Jan-Feb 2017.
[Is] ISSN:1665-2681
[Cp] País de publicação:Mexico
[La] Idioma:eng
[Ab] Resumo: Background and aims. Pegylated interferon (Peg-INF) and ribavirin (RBV) based therapy is suboptimal and poorly tolerated. We evaluated the safety, tolerability and efficacy of a 24-week course of sofosbuvir plus daclatasvir without ribavirin for the treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) in both HCV-monoinfected and human immunodeficiency virus (HIV)-HCV coinfected patients. MATERIAL AND METHODS: We retrospectively evaluated 22 consecutive adult LT recipients (16 monoinfected and 6 coinfected with HIV) who received a 24-week course of sofosbuvir plus daclatasvir treatment under an international compassionate access program. RESULTS: Most patients were male (86%), with a median age of 58 years (r:58-81y). Median time from LT to treatment onset was 70 months (r: 20-116 m). HCV genotype 1b was the most frequent (45%), 55% had not responded to previous treatment with Peg-INF and RBV and 14% to regiments including first generation protease inhibitors. Fifty-six percent of the patients had histologically proven cirrhosis and 6 had ascites at baseline. All patients completed the 24-week treatment course without significant side effects except for one episode of severe bradicardya, with only minor adjustments in immunosuppressive treatment in some cases. Viral suppression was very rapid with undetectable HCV-RNA in all patients at 12 weeks. All 22 patients achieved a sustained virological response 12 weeks after treatment completion. CONCLUSION: The combination of sofosbuvir plus daclatasvir without ribavirin is a safe and effective treatment of HCV recurrence after LT in both monoinfected and HIV-coinfected patients, including those with decompensated cirrhosis.
[Mh] Termos MeSH primário: Antivirais/administração & dosagem
Coinfecção
Doença Hepática Terminal/cirurgia
Infecções por HIV/virologia
Hepacivirus/efeitos dos fármacos
Hepatite C/tratamento farmacológico
Imidazóis/administração & dosagem
Cirrose Hepática/tratamento farmacológico
Transplante de Fígado/efeitos adversos
Sofosbuvir/administração & dosagem
Ativação Viral
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Antivirais/efeitos adversos
Ensaios de Uso Compassivo
Esquema de Medicação
Quimioterapia Combinada
Doença Hepática Terminal/diagnóstico
Doença Hepática Terminal/virologia
Feminino
Infecções por HIV/diagnóstico
Hepacivirus/genética
Hepacivirus/patogenicidade
Hepatite C/diagnóstico
Hepatite C/virologia
Seres Humanos
Imidazóis/efeitos adversos
Imunossupressores/administração & dosagem
Cirrose Hepática/diagnóstico
Cirrose Hepática/virologia
Masculino
Meia-Idade
RNA Viral/genética
Recidiva
Estudos Retrospectivos
Sofosbuvir/efeitos adversos
Fatores de Tempo
Resultado do Tratamento
Carga Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (BMS-790052); 0 (Imidazoles); 0 (Immunosuppressive Agents); 0 (RNA, Viral); WJ6CA3ZU8B (Sofosbuvir)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170105
[St] Status:MEDLINE
[do] DOI:10.5604/16652681.1226819



página 1 de 40 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde